Global angina pectoris market is anticipated to witness lucrative growth attributing to factors such as rising geriatric population base; rapidly increasing lifestyles associated changes that include smoking, prolonged stress and physical inactivity. Growing incidences of chronic diseases such as diabetes mellitus, hypertension and kidney disease is expected to provide a growth platform to the market. Launch of new pharmacological agents & technologically novel concepts such as angiogenesis/gene therapy, spinal stimulation, echocardiography, cardiac magnetic resonance imaging, transmyocardial laser revascularization and usage of metabolic modulators. These are being preferred more owing to benefits such as greater efficacy, reduced trauma and better patient safety and hence are expected to drive the demand for new market entrants in the angina pectoris market over the forecast period.
The global angina pectoris market is segregated on the basis of types into nitrates, calcium channel blockers, beta adrenoceptors antagonists, potassium channel openers. Nitrates market includes drugs such as glyceryl trinitrate, isosorbide mononitrate. Beta blockers market includes drugs such as verpamil, nifedipine, felodipine, diltiazem, nitrendipine, benidipine. Beta adrenoceptors market followed by nitrates dominated the global angina pectoris market in 2014. It is the first line of treatment owing to the availability of wider range of drugs within beta adrenoceptors. These provide benefits such as equal efficacy & magnitude, easy route of administration, amplified & prolonged therapeutic action and effectiveness on wider range of patient profiles.
Geographically, the angina pectoris market is segmented into North America, Europe, Asia Pacific, Latin America and MEA. North America constitutes the substantial market share of the angina pectoris market in 2014 as a consequence of rising growth factors such as sophisticated medical infrastructure, high disposable income, and high prevalence of lifestyle associated disease such as diabetes mellitus. Furthermore, higher vulnerability of population base due to obesity, smoking, dietary interventions factors for angina pectoris are expected to further drive the market over the forecast period. Asia Pacific is anticipated to attain incremental growth over the forecast period, owing to rise in awareness of disease, improving medical infrastructure, new market entrants, increasing incidences of high cholesterol levels, obesity, higher mortality rates and increasing geriatric population.
The key players of the angina pectoris market are Anthera Pharmaceuticals, Astellas Pharma, Sanofi, Cardium Therapeutics, Cardeus Pharmaceuticals and CardioVascular BioTherapeutics (CVBT), Bayer HealthCare, Ark Therapeutics Group plc, Merck & Co. Inc., Circ Pharma Limited, Torrent Pharmaceuticals Limited, Pfizer Inc., HUYA Bioscience International LLC, G.D. Searle LLC, Novartis Pharmaceutical Corporation, 3M Pharmceuticals, Lacer S.A., Biovail Laboratories, Viromed Co Ltd., and Baxter Healthcare Corporation. These market players are expected to work upon serving the unmet market needs, identifying new targets and consequentially develop stronger drug pipelines. Moreover, rising untapped opportunities for new market players owing to weak competition and presence of inefficient therapeutics is anticipated to further drive the market growth.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.